If a COVID-19 vaccine were authorized for emergency use, it would occur without pre-license inspections of the manufacturing facilities, a US FDA official acknowledged at a 22 October meeting of the agency’s Vaccines and Related Biological Products Advisory Committee.
The agency might instead simply visit the facilities.







